Navigation Links
Instead of Preventing Infections, Silver Coated Needleless IV Connectors May Actually Cause Them, a Nationally-Recognized Expert Tells National Conference on Cancer Nursing Research
Date:2/11/2011

LOS ANGELES, Feb. 11, 2011 /PRNewswire/ -- Nationally-acclaimed researcher and award-winning author Dr. Cynthia C. Chernecky warned in a speech at the 11th National Conference on Cancer Nursing Research that silver treated IV connectors could actually cause potentially deadly infections they were supposed to prevent.

After testing antimicrobial effectiveness of three different needleless IV connector devices with silver coated or silver impregnated fluid pathway components, Dr. Chernecky, PhD, RN, AOCN, FAAN, said that despite FDA clearance of silver coatings, she found they actually grew bugs capable of causing potentially fatal infections.

Presenting to the Oncology Nursing Society and American Cancer Society, the nation's highest-level conference on oncology nursing, Dr. Chernecky's podium address was a wake-up call to leaders in the nursing profession in attendance.  A professor of Physiological and Technological Nursing at Georgia Health Sciences University, Dr. Chernecky was invited to deliver her remarks in one of the conference's prestigious podium presentations.  She is author of 30 books on nursing, including one on "Advance and Critical Care Nursing" that won the distinguished American Journal of Nursing "Book of the Year" Award.

Asked in an interview following her talk how silver-coatings received FDA clearance, Dr. Chernecky said the FDA was presented with evidence from the manufacturers that their silver treated needleless IV connectors were effective in killing bugs.  But when blood comes in contact with the silver coated or impregnated fluid pathway components in practical use, the silver loses its bug-killing capability and an intraluminal or biofilm condition is created that actually nourishes bacteria.  

"The FDA should consider requiring a blood component test protocol when evaluating needleless IV connector products, just as if you were testing a coffee maker you'd want coffee in it to see how good it brews."

According to Dr. Chernecky, all three silver coated/impregnated IV connectors tested grew enough Staphylococcus aureus and Staphylococcus epidermidis bacteria to induce infections. She noted a recent FDA Alert & Notification letter which requires manufacturers of positive displacement IV connectors to prove their devices do not increase catheter-related bloodstream infection (CRBSI) risk. Numerous studies already associate positive displacement connecters with higher rates of CRBSI.

Studies also associate negative displacement needleless IV connectors with higher CRBSI rates, she said, due to higher rates of occlusion. Studies have shown that positive and negative displacement connectors appear unable to control bacterial growth, which may be due in part to the bacteria-nurturing effect of blood reflux within the catheter lumen and the dead space within many of the IV connector fluid pathways that entrap blood and are difficult to effectively flush.  

Dr. Chernecky noted in the last 21 years only one new technology-based needleless IV connector has emerged, an intraluminal protection device (IPD) from RyMed Technologies, a company that has been struggling to penetrate a hospital market dominated by older IV connector systems with either positive or negative displacement.  RyMed's device has zero displacement and therefore is not subject to blood reflux, which may help explain its effectiveness in reducing infections to zero or very near zero at hospitals, home infusion and extended care facilities where it's in use. One of the leading hospital-acquired infections, CRBSI is fatal in up to 25% of cases.

CONTACT: Glen Calder, 561-750-9800 x216

gcalder@transmediagroup.com




'/>"/>
SOURCE Dr. Cynthia C. Chernecky
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
2. China PharmaHub Corp. Begins Trading Under Stock Symbol CPHB Instead of WRLC
3. FDAs Just Approved Monthly Drug Treatment, Vivitrol Could Be Game Changer, Says Countrys Largest Drug Treatment Recovery President, CRCs Jerry Rhodes; Provides Addicts One Decision A Month Instead of 30
4. Nationwide Survey Reports that Mothers View Cleaning Homes and Toys as Essential to Preventing Colds & Flu
5. Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice
6. Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Mens Health Week Is June 9-15)
7. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
8. Physicians Health Study II Finds No Magic Bullet for Preventing Cardiovascular Disease
9. March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots
10. Value of Genetic Testing for Preventing Blood Clots Unproven, According to New AHRQ Study
11. HIV Vaccine Study First to Show Some Effectiveness in Preventing HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... and Strategies - 2016" report to their offering. ... The latest research Autism ... pricing data and benchmarks in the global Autism Spectrum Disorder market. ... What are the key drugs marketed for Autism Spectrum Disorder ...
(Date:2/23/2017)... -- ITL Limited, ( ASX: ITD ), an innovative diversified healthcare ... ended 31 December 2016 compared with the previous corresponding period. A ... here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: 1.2 ... $15.7m; up 11%) Profit before tax of $2.12m ...
(Date:2/23/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs Price ... in the global Oesophageal Cancer market. The research answers ... key drugs marketed for Oesophageal Cancer and their clinical attributes? How ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... ... disabilities, it is so critically important that we all are aware of our ... why Mediaplanet is proud to announce the launch of its newest edition of ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Yisrayl Hawkins, ... focuses on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement ... current generation. He explains that the Bible details the current times so plainly ...
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to Head ... division on February 12th. Ms. Esparza qualified into this prestigious status after ... held in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts in ...
(Date:2/23/2017)... FL (PRWEB) , ... February 23, 2017 , ... ... non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma ... – will return to the La Gorce Country Club in Miami Beach to ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... in thought leadership , media relations, content marketing, social media management, corporate ... several clients already in the state and in nearby New Hampshire, Massachusetts and ...
Breaking Medicine News(10 mins):